In this illustration, the Netflix logo can be seen displayed on a smartphone screen, with a representation of the stock market in the background.
Pictures of Sopa | Missile | beautiful pictures
Check out the companies that make headlines in midday trading.
Netflix — The streaming giant grew 6.3% later Dual upgrade to buy from sell by CFRA. The company said it will be difficult for competitors to catch up with the company.
Cal-Maine Food — Cal-Maine shares fell 15% after reporting earnings that fell short of Wall Street expectations even as the egg maker reported record revenue. The company said the outbreak of bird flu limited supply and pushed up prices.
Southwest Airlines — The airline’s stock rose more than 3%, making up for losses from the previous session when it fell more than 5%. Violently the disruption at Southwest Airlines drew excessive criticism from frustrated travelers who have dealt with thousands of canceled flights from airlines this week because of winter weather. Southwest Airlines canceled an additional 60% of flights on Wednesday. According to the Dallas Morning News, is expected to restore the full schedule on Friday.
Lockheed Martin — Shares of the defense contractor rose nearly 1% after news that its Sikorsky unit was in dispute over a U.S. Army helicopter contract awarded to document. It said proposals for the $1.3 billion contract had not been evaluated fairly. Textron stock ended up gaining 1.9%.
Tesla — Tesla stock is up more than 7% after selling off in previous sessions and 37% this month. Stocks are heading for one of the worst months, quarters and years ever.
Apple — Shares of the iPhone maker rose more than 3% after hitting their lowest since June 2021 earlier in the week.
synthetic electricity — Shares rose 1.7% amid news that General Electric’s healthcare subsidiary will join the S&P 500 when it begins private trading on Jan. 4. GE Healthcare will replace position Vornado Real Estate Trustprepare to join the S&P MidCap 400.
immune genes Shares rose 6.2% after the biotech company announced CFO Susan Altschuller would not be returning from her retirement. Renee Lentini, vice president and chief accounting officer, was appointed interim chief financial officer. Stock initially fell in premarket trading.
Treatment of TG — Biopharmaceutical stock up more than 29% on news The US Food and Drug Administration has approved its drug for the treatment of relapsing forms of multiple sclerosis. The drug, called Briumvi, is expected to hit the market in the first quarter of 2023.
— CNBC’s Alex Harring and Sarah Min contributed reporting
